These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 35123433)
1. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia. Bourrier N; Landego I; Bucher O; Squires M; Streu E; Hibbert I; Whiteside T; Gibson SB; Geirnaert M; Johnston JB; Dawe DE; Banerji V BMC Cancer; 2022 Feb; 22(1):148. PubMed ID: 35123433 [TBL] [Abstract][Full Text] [Related]
2. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. Herishanu Y; Shaulov A; Fineman R; Bašić-Kinda S; Aviv A; Wasik-Szczepanek E; Jaksic O; Zdrenghea M; Greenbaum U; Mandac I; Simkovic M; Morawska M; Benjamini O; Spacek M; Nemets A; Bairey O; Trentin L; Ruchlemer R; Laurenti L; Stanca Ciocan O; Doubek M; Shvidel L; Dali N; Mirás F; De Meûter A; Dimou M; Mauro FR; Coscia M; Bumbea H; Szász R; Tadmor T; Gutwein O; Gentile M; Scarfò L; Tedeschi A; Sportoletti P; Gimeno Vázquez E; Marquet J; Assouline S; Papaioannou M; Braester A; Levato L; Gregor M; Rigolin GM; Loscertales J; Medina Perez A; Nijziel MR; Popov VM; Collado R; Slavutsky I; Itchaki G; Ringelstein S; Goldschmidt N; Perry C; Levi S; Polliack A; Ghia P Am J Hematol; 2020 Jun; 95(6):604-611. PubMed ID: 32096887 [TBL] [Abstract][Full Text] [Related]
3. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group. Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885 [TBL] [Abstract][Full Text] [Related]
4. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093 [TBL] [Abstract][Full Text] [Related]
5. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969 [TBL] [Abstract][Full Text] [Related]
6. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. Greil R; Tedeschi A; Moreno C; Anz B; Larratt L; Simkovic M; Gill D; Gribben JG; Flinn IW; Wang Z; Cheung LWK; Nguyen AN; Zhou C; Styles L; Demirkan F Ann Hematol; 2021 Jul; 100(7):1733-1742. PubMed ID: 34018029 [TBL] [Abstract][Full Text] [Related]
7. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452 [TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis. Długosz-Danecka M; Jurczak W; Łątka-Cabała E; Morawska M; Gawroński K; Wiśniewska A; Dudziński M; Wąsik-Szczepanek E; Chmielowska E; Łabędź A; Wdowiak K; Hus I Pol Arch Intern Med; 2018 Aug; 128(7-8):421-426. PubMed ID: 30057377 [TBL] [Abstract][Full Text] [Related]
10. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia. Jean GW; Comeau JM Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688 [TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Seiter K; Mamorska-Dyga A Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852 [TBL] [Abstract][Full Text] [Related]
12. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681 [TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab for the treatment of chronic lymphocytic leukemia. Rogers KA; Jones JA Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589 [TBL] [Abstract][Full Text] [Related]
14. Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab. Dawson K; Moran M; Guindon K; Wan H Clin J Oncol Nurs; 2016 Apr; 20(2):E41-8. PubMed ID: 26991722 [TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia. Shah A Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849 [TBL] [Abstract][Full Text] [Related]
17. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Leblond V; Aktan M; Ferra Coll CM; Dartigeas C; Kisro J; Montillo M; Raposo J; Merot JL; Robson S; Gresko E; Bosch F; Stilgenbauer S; Foà R Haematologica; 2018 Nov; 103(11):1889-1898. PubMed ID: 29976743 [TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison. Van Sanden S; Baculea S; Diels J; Cote S Adv Ther; 2017 Jul; 34(7):1650-1661. PubMed ID: 28573505 [TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation. Kakkar AK; Balakrishnan S J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578 [TBL] [Abstract][Full Text] [Related]
20. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. Ladyzynski P; Molik M; Foltynski P Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]